Oxford BioDynamics Plc (OBD) has announced that Vulpes Testudo Fund, controlled by Non-Executive Director Stephen Diggle, has sold 777,000 Ordinary Shares of 1 pence each at an average price of 38.3p. Following this transaction, Diggle is interested in a total of 27,556,756 shares, representing approximately 13.62% of the Company's current issued share capital. The transaction was conducted on the London Stock Exchange. OBD is a global biotechnology company that develops and commercializes precision medicine tests for life-changing diseases. Its flagship products include the EpiSwitch CiRT (Checkpoint Inhibitor Response Test) and EpiSwitch PSE (EpiSwitch Prostate Screening test) blood tests. OBD has also launched the EpiSwitch CST (Covid Severity Test) and the EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling and biomarker discovery. The company's product portfolio is based on its proprietary 3D genomic biomarker platform, EpiSwitch, which can build molecular diagnostic classifiers for various indications. OBD has partnered with big pharma and leading institutions, including Pfizer, Roche, and Mayo Clinic. The company is headquartered in Oxford, UK, and is listed on AIM of the London Stock Exchange.